All information is correct at the time of publication.
Date published: 1 November 2025
Click on the links in the table for more information about the disease each vaccine protects against.
| Age due | Diseases protected against | Vaccine and name | Usual site1 | ||
|---|---|---|---|---|---|
|
8 weeks old |
DTaP/IPV/Hib/ HepB (6-in-1) |
Infanrix hexa® or Vaxelis® |
Thigh |
||
| Meningococcal group B (MenB) |
MenB |
Bexsero® |
Thigh |
||
| Rotavirus gastroenteritis |
Rotavirus |
Rotarix® |
By mouth |
||
| 12 weeks old | Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | DTaP/IPV/Hib/ HepB (6-in-1) | Infanrix hexa® or Vaxelis® | Thigh | |
| Meningococcal group B | MenB | Bexero® | Thigh | ||
| Rotavirus gastroenteritis | Rotavirus | Rotarix® | By mouth | ||
|
16 weeks old |
Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | DTaP/IPV/Hib/ HepB (6-in-1) | Infanrix hexa® or Vaxelis® | Thigh | |
| Pneumococcal | PCV 13 | Prevenar 13®2 | Thigh | ||
| 12 months old | Born before 1 July 2024 | Born on or after 1 July 2024 | |||
| Pneumococcal | Pneumococcal | PCV 13 | Prevenar 13® | Upper arm/ thigh | |
| Meningococcal group B | Meningococcal group B | MenB | Bexsero® | Upper arm/ thigh | |
| Measles, mumps and rubella | Measles, mumps and rubella | MMR | MMRVaxPro® or Priorix® | Thigh | |
| Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | DTaP/IPV/Hib/HepB (6-in-1) | Infanrix hexa® or Vaxelis® | Thigh | ||
| 18 months old | Born before 1 July 2024 | Born on or after 1 July 2024 | |||
| No appointment | Measles, mumps and rubella | MMR | MMRVaxPro® or Priorix® | Upper arm/thigh | |
| No appointment | Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | DTaP/IPV/Hib/ HepB (6-in-1) | Infanrix hexa® or Vaxelis® | Upper arm/thigh | |
| 22 and 3 years old and all school aged children | Influenza (annually from September) | Live attenuated influenza vaccine3 | Fluenz®4 | Both nostrils | |
| 3 years 4 months old | Born before 1 July 2024 | Born on or after 1 July 2024 | |||
| Diphtheria, tetanus, pertussis and polio | Diphtheria, tetanus, pertussis and polio | dTaP/IPV (4-in-1) | Boostrix-IPV® or Repevax® | Upper arm | |
| Measles, mumps and rubella | MMR | MMRVaxPRO® or Priorix® | Upper arm | ||
| School year 8 (12 to 13 year olds) |
Cervical cancer, some head and neck and ano-genital cancers, and genital warts caused by human papillomavirus (HPV) | HPV5 (one dose) | Gardasil 9® | Upper arm | |
| School year 9 (13 and 14 year olds) |
Tetanus, diphtheria and polio | Td/IPV (3-in-1) (check MMR status) | Revaxis® | Upper arm | |
| Meningococcal groups A, C, W and Y | MenACWY | Nimenrix® or MenQuadfi® | Upper arm | ||
| 65 years of age and older | Influenza (annually) | Inactivated influenza vaccine |
Adjuvanted trivalent influenza vaccine (aTIV) Cell-based trivalent influenza vaccine (TIVc)6 |
Upper arm | |
| 65 years of age | Pneumococcal | PPV23 | Pneumovax 23® | Upper arm | |
|
65 years old and 70 to 79 years old (plus people from age 18 with severe immunosuppression)7 |
Shingles | Shingles | Shingrix®8 | Upper arm | |
| 75 years old | Respiratory Syncytial Virus (RSV) | RSV | Abrysvo® | Upper arm | |
1 Where two or more injections are required at once, these should ideally be given in different limbs. Where this is not possible, injections in the same limb should be given 2.5cm apart. For more details see Chapter 4 (external site) and Chapter 11 (external site) in the Green Book (external site). All injected vaccines are given intramuscularly unless stated otherwise. Check relevant Green Book chapters regarding co-administration of vaccines.
2 Refer to the Green Book Chapter: Pneumococcal - table 25.3 (external site) for babies with asplenia, splenic dysfunction, complement disorder or severely immunocompromised.
3 Children must be 2 years old by 31 August to receive influenza vaccine in the routine programme in autumn/winter.
4 If Fluenz® is contraindicated, use a suitable age-appropriate inactivated flu vaccine.
5 Check the relevant chapter of the Green Book for individuals requiring a 3-dose schedule.
6 Only use TIVc if no aTIV stock is available or if aTIV is unsuitable.
7 Refer to Green Book Chapter: Shingles (external site) for further details and definition of severe immunosuppression.
8 Immunocompetent individuals require two doses of Shingrix® with the second dose given 6 to 12 months after the first dose. Severely immunosuppressed individuals require two doses with the second dose given 8 weeks to 6 months after the first dose.
| Target group | Age and schedule | Disease | Vaccines |
|---|---|---|---|
| Babies born to hepatitis B infected mothers |
At birth and 1 month old1 |
Hepatitis B | Hepatitis B vaccines (Engerix B® / HBvaxPRO®) |
| Infants in areas of the country with TB incidence >= 40/100,000 | From birth | Tuberculosis | BCG® |
| Infants with a parent or grandparent born in a high incidence country2 | From birth | Tuberculosis | BCG® |
| People in a risk group for influenza3 | From 6 months to 64 years | Influenza | LAIV for children aged 2-17 years. Appropriate inactivated flu vaccine for people aged 18 years or older or if LAIV is contraindicated or otherwise unsuitable |
| Pregnant women | From 16 weeks of pregnancy | Pertussis |
Tdap (ADACEL®) If ADACEL® is unavailable or contraindicated, administer dTaP/IPV (Boostrix-IPV or Repevax) |
| From 28 weeks of pregnancy | Respiratory syncytial virus (RSV) | Abrysvo® | |
| At any stage in pregnancy during the flu season | Influenza | Inactivated flu vaccine | |
| Gay, bisexual and other men who have sex with men |
45 years of age and under4 |
HPV4 | Gardasil 9® |
1 In addition to hexavalent vaccine (Infanrix hexa or Vaxelis) given at 8, 12, 16 weeks and 18 months. Take blood for HBsAg to exclude infection at 12 to 18 months.
2 Where the annual incidence of TB is >= 40/100,000 see the WHO country profile
3 Refer to annual flu Welsh Health Circular (WHC) for eligibility.
4 Check the Green Book Chapter: HPV (external site) for individuals requiring a 1, 2 or 3 dose schedule.
| Medical condition | Diseases protected against | Vaccines required2 |
|---|---|---|
| Asplenia, splenic dysfunction or complement disorder (Including people with coeliac disease who have splenic dysfunction, and all haemoglobinopathies such as homozygous sickle cell disease) |
Meningococcal groups A, B, C, W and Y
|
MenACWY Annual flu vaccine4 |
| Cochlear implants, cerebrospinal fluid leaks | Pneumococcal | PPV23 (from two years of age)3 |
| Chronic respiratory and heart conditions (such as moderate to severe asthma, chronic pulmonary disease, and heart failure) |
|
PPV23 (from two years of age)3 Annual flu vaccine4 |
| Chronic neurological conditions (such as Parkinson’s or motor neurone disease, or learning disability) |
Pneumococcal (only if the individual is also at increased risk of aspiration) |
PPV23 (from two years of age)3 Annual flu vaccine4 |
| Diabetes |
|
PPV23 (from two years of age)3 Annual flu vaccine4 |
|
Chronic kidney disease (CKD) |
Pneumococcal (stage 4 and 5 CKD) Influenza (stage 3, 4 and 5 CKD) Hepatitis B (stage 4 and 5 CKD) |
PPV23 (from two years of age)3 Annual flu vaccine4 Hepatitis B |
| Chronic liver conditions | Pneumococcal Influenza Hepatitis A & B |
PPV23 (from two years of age)3 Annual flu vaccine4 Hepatitis A & Hepatitis B |
| Haemophilia | Hepatitis A & B | Hepatitis A & Hepatitis B |
| Immunosuppression due to disease or treatment | Pneumococcal Influenza Shingles |
PPV23 (from two years of age)5 Annual flu vaccine4 Shingrix (aged 18 years and over)6 |
1 The list is not exhaustive. Other vaccines may be recommended for certain individuals.
2 Check relevant chapter of the Green Book for specific schedule and for further detail.
3 See table 25.3 – Summary of vaccine doses for at-risk patients in the Green Book, Chapter 25: Pneumococcal for further information.
4 From six months of age.
5 Refer to the Green Book Chapter: Pneumococcal (external site) for detailed guidance on vaccine recommendations for this clinical risk group.
6 Check the Green Book Chapter: Shingles (external site) for further information, including: definition of severe immunosuppression and interval for second dose.